Objective: Analysis of twins with epilepsy to explore the genetic architecture of specific epilepsies, to evaluate the applicability of the 2010 International League Against Epilepsy (ILAE) organization of epilepsy syndromes, and to integrate molecular genetics with phenotypic analyses.
Results: Of 558 twin pairs, 418 had confirmed seizures. A total of 534 twin individuals were affected. There were higher twin concordance estimates for monozygotic (MZ) than for dizygotic (DZ) twins for idiopathic generalized epilepsies (MZ 5 0.77; DZ 5 0.35), genetic epilepsy with febrile seizures plus (MZ 5 0.85; DZ 5 0.25), and focal epilepsies (MZ 5 0.40; DZ 5 0.03). Utilizing the 2010 ILAE scheme, the twin data clearly demonstrated genetic influences in the syndromes designated as genetic. Of the 384 tested twin individuals, 10.9% had mutations of large effect in known epilepsy genes or carried validated susceptibility alleles.
Conclusions: Twin studies confirm clear genetic influences for specific epilepsies. Analysis of the twin sample using the 2010 ILAE scheme strongly supported the validity of grouping the "genetic" syndromes together and shows this organizational scheme to be a more flexible and biologically meaningful system than previous classifications. Successful selected molecular testing applied to this cohort is the prelude to future large-scale next-generation sequencing of epilepsy research cohorts. Insights into genetic architecture provided by twin studies provide essential data for optimizing such approaches. Neurology ® 2014;83:1042-1048 GLOSSARY BECTS 5 benign epilepsy with centrotemporal spikes; CAE 5 childhood absence epilepsy; DS 5 Dravet syndrome; DZ 5 dizygotic; FE 5 focal epilepsies; FS 5 febrile seizures; FS1 5 febrile seizures plus; GE 5 generalized epilepsies; GEFS1 5 genetic epilepsy with febrile seizures plus; IFE 5 idiopathic focal epilepsies; IGE 5 idiopathic generalized epilepsies; ILAE 5 International League Against Epilepsy; IPOE 5 idiopathic photosensitivity occipital epilepsy; JME 5 juvenile myoclonic epilepsy; MAS 5 epilepsy with myoclonic-atonic seizures; MZ 5 monozygotic; SGE 5 symptomatic generalized epilepsies; SSCP 5 single-stranded conformation polymorphism; TLE 5 temporal lobe epilepsy.
William Lennox, 1 a pioneering epileptologist, realized the value of twin studies in genetics, highlighting "the testimony of twins" in his monumental 1960 book. 2 His work predated formal classification systems and his cohort was clinically ascertained. Later population-based twin studies minimized ascertainment bias, but lacked precision in syndrome diagnoses. [3] [4] [5] [6] [7] Subsequent twin research utilizing the 1989 International League Against Epilepsy (ILAE) classification system 8 incorporating both syndromic analyses and population samples showed clear genetic influences for generalized epilepsies (GE), febrile seizures (FS), and even for focal epilepsies (FE). 9, 10 Indeed, reanalysis of Lennox's original data largely confirmed strong genetic influences for broad epilepsy syndromes.
To incorporate major neuroscientific advances in understanding human epilepsies, the ILAE developed revised terminology and concepts for organization of seizures and epilepsies in 2010. 12 This framework, which is not yet a formal scientific classification, provides flexible concepts that better reflect our current understanding of epilepsies, 12 especially in genetics. 13 Channelopathies are a major known mechanism in idiopathic epilepsies, [14] [15] [16] but non-ion channel genes such as LGI1, 17 SLC2A1, 18, 19 and DEPDC5 20 are also important causes of Mendelian epilepsies. Susceptibility alleles are much more challenging to confirm, but some, such as variants in CACNA1H and the 15q13.3 microdeletion, are established. 21, 22 We analyze the genetic influences for specific epilepsy syndromes with a large twin cohort, incorporating advances in syndromic diagnoses. Next, we review the utility of the 2010 ILAE organizational scheme. 12 Finally, we analyze the yield of selected molecular genetic testing applied to this cohort.
METHODS Ascertainment of twins and clinical assessment. Twins were ascertained since 1988 from multiple twin registries or by referral; all cases were Australian. The clinical methodology as detailed in our earlier report comprised clinical assessment, rigorous record review, EEG, and follow-up. 10 If the diagnostic evaluation excluded true epileptic seizures, the twin individual was labeled as false-positive. If a twin had an EEG abnormality, but no history of seizures, he or she was classified as unaffected.
Our earlier study reported 358 pairs with definite or suspected seizures 10 ; here we increased the cohort to 558 pairs. Twin diagnoses have been updated since initial ascertainment due to follow-up data and evolving diagnoses. All early twin pairs were re-reviewed as new syndromes such as genetic epilepsies with FS plus (GEFS1) were introduced and others such as Dravet syndrome (DS) were better recognized.
In the early cohort, analyses of red cell antigens and human leukocyte antigen markers were performed to confirm zygosity, whereas in the later cohort at least 9 different polymorphic DNA markers were assayed. If all markers were concordant, the twin pairs were designated monozygotic (MZ). In cases where the laboratory zygosity was not performed, zygosity was determined on clinical findings and a zygosity questionnaire, which has greater than 95% accuracy. 1989 ILAE classification of epilepsies. The general framework was based on the ILAE classification of epilepsies and epileptic syndromes, as previously described. 8 Briefly, twin individuals were divided into 5 broad epilepsy groups, which consisted of GE, FE, FS alone, special syndromes, and unclassified epilepsies. Twin individuals could be classified into more than one broad epilepsy group. FS were included in their own broad group to enable separate analyses. The broad epilepsy groups were then divided using the 1989 ILAE classification. 8 GE were divided into idiopathic GE (IGE), GEFS1 spectrum, symptomatic GE (SGE), and unclassified GE. IGE included childhood absence epilepsy (CAE), juvenile absence epilepsy, and juvenile myoclonic epilepsy (JME). The GEFS1 spectrum included a range of phenotypes including FS plus (FS1), epilepsy with myoclonic-atonic seizures (MAS), and DS. 24 FE were divided into idiopathic FE (IFE), idiopathic photosensitivity occipital epilepsy (IPOE), symptomatic FE, and unclassified FE. For temporal lobe epilepsy (TLE), because of emerging evidence of a major genetic component in cases without lesions, 25 we also used a specific category of nonlesional TLEs as these fall under the 1989 definition of IFE. We included cases with clinical or electrographic support for temporal lobe seizure origin, without structural abnormalities on MRI.
2010 ILAE organization of the epilepsies. In this scheme, the underlying cause was categorized into 3 groups-genetic, structural/metabolic, and unknown. 12 Genetic presumes the epilepsy syndrome is a direct cause of a known or presumed genetic defect, where seizures are the main symptom of the disorder. 12 Structural/metabolic causes are where these distinct causes were associated with an increased risk of epilepsies. Even if the structural cause may also be due to a genetic defect, there is a separate disorder interposed between the genetic defect and epilepsy. 12 Terminology from the old classification system such as symptomatic and cryptogenic was no longer in the new organization; hence these cases were reclassified using the new terminology. The original symptomatic focal group was reviewed and divided into lesional TLEs and other lesional FE. Lesional was defined by the presence of a structural abnormality on MRI. Cryptogenic FE were generally designated as nonlesional TLEs (see above) and other FE.
The original SGE group was also reviewed and divided into malformations of cortical development, progressive myoclonic epilepsies, and others (including epilepsy of infancy with migrating focal seizures and unclassified).
The neonatal seizure group from the old classification was reviewed and divided into benign neonatal seizures and other epilepsies with neonatal seizures (incorporating those associated with other seizure disorders or unclassified).
Molecular testing. Molecular testing was not carried out for the whole cohort. Twin individuals were tested when they had syndromes suspected to be associated with variation in specific genes. Twin individuals who were tested and had genomic variants for either genes of large effect or susceptibility alleles for the few known genes for epilepsies with complex inheritance were studied further for concordance or nonconcordance of epilepsy phenotype.
Patients were screened for mutations in SCN1A by denaturing high-performance liquid chromatography and for mutations or variants in other genes by single-stranded conformation polymorphism (SSCP) analysis. Sequence variants detected by either screening method were analyzed by direct Sanger sequencing.
Statistical methods. Casewise concordance, defined as the probability that one member of a twin pair is affected given that the other is affected, was estimated as P c 5 2n c /(2n c 1 n d ), where n c is the number of concordant pairs and n d the number of discordant pairs. Under the assumption of complete ascertainment of seizure status, this is an unbiased estimator with asymptotic
. 26 The hypotheses that concordance was independent of zygosity, and disease subtype, were tested using the likelihood ratio criterion. That is, the log-likelihood for a model estimating a single concordance for all twin pairs pooled was subtracted from the sum of the log-likelihoods for a model estimating concordance separately for MZ and dizygotic (DZ) pairs and this statistic was compared to a x 2 distribution with 1 degree of freedom. All quoted p values were 2-sided.
In those twin individuals classified as having more than one broad epilepsy group diagnosis, concordances were estimated for each broad group. In the cases where FS or special syndromes occurred in association with epilepsy syndromes (generalized, focal, or unclassified epilepsies), they were classified by concordance for the epilepsy syndrome only.
Where twin pairs were concordant for a broad syndrome, but discordant for a specific syndrome, they were counted once (as discordant) in the specific syndrome analysis, with only the proband's syndrome listed.
RESULTS Cohort characteristics. There were a total of 1,116 twin individuals (558 twin pairs) in the cohort.
Ascertainment of twins was predominantly from twin registries (69%) with direct referral accounting for 31%. There were 651 female (53%) and 465 male (47%) participants. There were 6 triplet sets in the database; these were analyzed as single pairs in order not to inflate their effect on the analysis. In 5 of the triplet sets, only 1 was affected, hence 1 unaffected triplet was excluded to enable the set to be counted as a single discordant "twin" pair. In the final set, all 3 had IGE and were counted as a single concordant pair.
There were 158 twin individuals who were deemed as false-positive for epilepsies. Although they selfreported seizures or suspected seizures, after clinical review other diagnoses were made. The false-positive diagnoses were syncope (n 5 44), breath-holding (n 5 29), behavioral events (n 5 13), febrile syncope (n 5 10), movement disorders (n 5 5), night terrors (n 5 3), reflux (n 5 3), migraine (n 5 2), and uncertain (n 5 49). The 158 false-positive twin individuals were part of 140 twin pairs classified as false-positives, as some twin pairs were concordant for false-positive diagnoses. After excluding these 140 false-positive twin pairs, there were 418 twin pairs for analysis. Table 1 shows zygosity and seizure concordance in 418 twin pairs, including 534 affected twin individuals.
1989 ILAE classification of epilepsies. The 534 twin individuals were classified into the broad epilepsy groups of GE, FE, FS, special syndromes, and unclassified epilepsies. If twin individuals were classified with more than one broad group, concordances were determined for each broad group, leading to a total of 457 diagnostic comparisons from the 418 twin pairs.
Casewise concordances for seizures and broad epilepsy groups. Table 2 shows the casewise concordance estimates for all seizures and broad epilepsy groups. The estimated MZ casewise concordances were significantly different from the estimated DZ casewise concordances for the occurrence of seizures as a whole, as well as the broad epilepsy groups of generalized, focal, and febrile seizures. The estimated MZ casewise concordance for GE was higher than that for FE (0.79 vs 0.40, p , 0.0001). Similarly, the estimated DZ casewise concordance was higher for GE compared with FE (0.29 vs 0.03, p 5 0.002).
Casewise concordances for specific syndromes. Table 3 shows that all GE syndromes had higher MZ casewise concordance estimates compared with DZ casewise concordance estimates. As previously reported, 27 in the FE, there was striking MZ and DZ discordance for benign epilepsy with centrotemporal spikes (BECTS) (MZ 5 0; DZ 5 0), despite long being regarded as an idiopathic epilepsy with a presumed genetic basis. The nonlesional temporal lobe group showed higher MZ casewise concordance compared with DZ casewise concordance (MZ 5 0.82; DZ 5 0; p 5 0.003).
GEFS1 spectrum. The GEFS1 spectrum was recognized after initiation of the twin study and reanalysis provides new insights. First, concordance estimates (MZ 5 0.85; DZ 5 0.25; p 5 0.0009) provide strong evidence of a major genetic effect. Second, among the 15 concordant MZ twin pairs with the GEFS1 spectrum, there was no further family history of seizures in 7 of the twin pairs. Only one MZ twin pair had more than 4 family members affected (ascertained by referral as a multiplex family). In the 14 DZ twin pairs with the GEFS1 spectrum, there was no other family history in 4 of the DZ twin pairs. There were 4 DZ twin pairs with greater than 4 affected and notably all these families were ascertained by referral.
2010 ILAE organization. Table 4 shows casewise concordances estimates for epilepsies divided into the 3 etiologic groups: genetic, structural/metabolic, and unknown.
Casewise concordances for genetic causes. As expected, there were higher MZ casewise concordance estimates compared with DZ casewise concordance estimates in the epilepsies deemed genetic in the 2010 scheme. In particular, the estimated MZ casewise concordances were higher than the estimated DZ casewise concordance in CAE, JME, FS1, MAS, FS alone, and benign neonatal seizures. In DS, there was a high MZ concordance estimate, but as there were no DZ twin pairs, a p value could not be calculated.
Casewise concordances for structural/metabolic causes.
In the lesional TLEs group and acute symptomatic seizures, there were no concordant MZ pairs, supporting a nongenetic basis to these epilepsies. The group with malformations of cortical development showed a trend toward higher concordances in MZ twin pairs compared with DZ twin pairs, but the sample size was small.
Casewise concordances for unknown causes. High MZ concordance was seen in the IPOE and nonlesional TLE group. No MZ concordance was seen in the neonatal seizure group, BECTS, or benign occipital epilepsy.
Molecular analysis. Molecular testing in twins was not systematic and was performed over a 15-year period in those twin individuals with symptoms or family history suggestive of syndromes with known genes.
There were 384 twin individuals tested out of the 534 twin individuals with seizures and gene variants were detected in 37 twin individuals, with a total of 42 variants found as some twin individuals had more than one detected gene variant. Mutations of large effect were found in 4.4% of twin individuals (n 5 17) and susceptibility variants in the few known susceptibility genes were found in 6.5% of twin individuals (n 5 25). The most common gene in which variation was detected was SCN1A, as 10/55 (18%) twin individuals were found to have this pathogenic mutation. DISCUSSION This twin analysis incorporates advances in syndromic diagnoses and molecular analyses on a larger cohort than previously reported, 10 facilitating clearer interpretation of the genetic influences for specific epilepsy syndromes and in particular the syndromic groups of IGE and GEFS1 spectrum.
Using the 1989 ILAE Classification, we confirm previous twin studies, showing there are clear genetic influences in GE, FE, and FS, as well as greater concordances in MZ twin pairs for GE compared with FE. Particularly important is the clear genetic influence in FE, especially when divided into specific syndromes. BECTS has long been assumed to be largely genetic in origin, but the twin data did not support this, with no MZ concordance in our study. Our analysis of the BECTS twins previously highlighted that the etiology and genetics of BECTS is more complicated than initially conceptualized. 27, 28 The twin data support genetic influences in nonlesional TLEs; within this grouping, familial TLE is the most important. 29, 30 A combination of twin and family data supports complex inheritance for most cases, 25 although there is the well-recognized exception of autosomal dominant FE with auditory features, often due to mutations in LGI1, 17,31 which was not identified in our twins.
9,10
GEFS1 was not described at the time of the 1989 classification. Previous research defining the GEFS1 spectrum was based on rare large multiplex families. 32, 33 Whereas these rare families demonstrate autosomal dominant inheritance, the marked phenotypic heterogeneity within and between families supports a more complex etiology. 33 The twin analysis confirms clear genetic influences for the GEFS1 spectrum, with very high MZ concordance estimates. However, important additional insights have been gained from the family histories of the twins, as additional affected family members were usually not found. Thus, while the twin data confirm that there is clearly a genetic influence in GEFS1, the actual inheritance pattern is usually complex, with the initially described large autosomal dominant families being the exception. Multiple genes of small effect, possibly in combination with environmental influences, stochastic factors, or epigenetic modifications, may all play a role in GEFS1. The clinical genetics of FS and their relationship to GEFS1 in this twin sample are explored elsewhere. 34 This analysis provided strong direct support for the value of the new 2010 ILAE organizational system. Notably, for syndromes deemed genetic, the twin data uniformly demonstrated high MZ concordance estimates (table 4), supporting the premise that these epilepsies have strong genetic influences. 12 Conversely, for the structural/metabolic group, the data supported nongenetic influences in the majority, with the exception of certain malformations and progressive myoclonic epilepsies that are known to have a genetic basis, but according to the new classification, "there is a separate disorder interposed between the genetic defect and the epilepsies." 12 The new classification facilitates a mechanism of separating syndromes for which genetic influences may either directly or indirectly cause epilepsies.
In the unknown causes group, the twin data presented a mixed picture, with genetic influences in some epilepsies and no genetic influences in others. This mixed group highlighted the potential flexibility of this system in an era of evolving understanding of the pathophysiology of epilepsies. For instance, for Nonlesional temporal lobe epilepsies (13, 5) familial TLEs, our evolving understanding of the genetic influences based on twin and family data 25, 29, 30 suggests that this group would be better placed in the genetic group. Similarly, our evolving understanding of IPOE supports a genetic basis for this disorder. 35 Understanding etiology and communicating to patients and families is an essential part of counseling and, in the case of epilepsies with a genetic etiology, this can be done in the clinic, even if specific genes are not known or identified. The study highlighted the potential role of the new etiologically based system and in particular its flexibility for the evolving understanding of the epilepsies. The molecular data complement the clinical twin studies and show an appreciable diagnostic yield in this largely community-acquired cohort, even using older, single gene-directed technologies. The most frequent gene in which mutations were identified was SCN1A, in keeping with this currently being the most clinically relevant epilepsy gene. 36 We acknowledge that this testing was incomplete, and our yield is a minimal estimate, particularly as techniques such as SSCP have an appreciable falsenegative rate with certain genes such as SCN1A.
37
These data highlight the potential to integrate wellestablished clinical data with molecular genetic findings and pave the way for targeted next-generation sequencing of large cohorts, which is likely to be the next phase in diagnosis, treatment guidance, and genetic counseling. 38, 39 Moreover, these data extend our understanding of the genetics and genetic interrelationships in the various epilepsy syndromes that is vital to strategic planning of nontargeted, genomewide discovery using next-generation sequencing.
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